The clinical benefit of the combination of MET- and EGFR-targeted therapies in patients with NSCLC with acquired MET amplification–mediated resistance to EGFR TKIs has been explored in clinical trials, with varying tolerability dependent upon the agents being combined.18 Our findings provide a rationale for future clinical evaluation of this combination approach, given its tolerability and efficacy in this case, for patients with EGFR and METex14 mutations. Here, MET is linked to non-small cell lung carcinoma.